Expect to See DOACs for Venous Thromboembolism Due to Cancer

June 2020

You'll continue to see a shift toward direct oral anticoagulants (Eliquis, etc) for cancer-associated venous thromboembolism (VTE).

We're used to seeing these patients on a low-molecular-weight heparin (LMWH), such as dalteparin...or warfarin as an alternative.

But evidence with DOACs is stacking up for VTE due to cancer.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
200+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get quote

Table of Contents

Immunizations Keep Immunizations on Track During COVID-19
Infectious Diseases Put Treatments for COVID-19 in Perspective
Diabetes Temper Buzz About the First Oral GLP-1 Agonist, Rybelsus
Dermatology Manage Skin Irritation Due to Handwashing and PPE
Infectious Diseases Settle Debate About Vancomycin or Fidaxomicin for C. diff
Opioids Avoid Switching Methadone Products in Patients With Opioid Use Disorder
Communication Enhance Your Telecommunication Skills
Anticoagulants Expect to See DOACs for Venous Thromboembolism Due to Cancer
Practice Weigh the Situation When Patients Ask About Expiration Dates
Poison Prevention Provide Strategies to Prevent Poisonings